FDA Class III Recall: Orient Pharma's Pitavastatin Tablets Fail Impurity Specifications, Impacting Teva Supply
Orient Pharma Co., Ltd. faces an FDA Class III recall for Pitavastatin Tablets due to failed impurity/degradation specifications. This voluntary, firm-initiated action impacts 57,504 bottles manufactured for Teva Pharmaceuticals, distributed in New Jersey. Procurement and regulatory teams must assess immediate supply chain disruptions and re-evaluate supplier quality oversight for Pitavastatin Calcium.
FDA Initiates Class III Recall for Orient Pharma's Pitavastatin Tablets Due to Impurities
The U.S. Food and Drug Administration (FDA) has announced a Class III recall, D-0526-2025, for Pitavastatin Tablets, 2 mg, manufactured by Orient Pharma Co., Ltd. Yunlin Plant, located in Yunlin County, Taiwan. This voluntary, firm-initiated recall, commenced on June 11, 2025, stems from the product failing to meet established impurity and degradation specifications. A significant quantity of 57,504 bottles, each containing 90 tablets, is affected. These products, identified by NDCs 0480-3631-98, 0480-3632-98, and 0480-3633-98, were manufactured for Teva Pharmaceuticals, Parsippany, NJ 07054, and distributed within New Jersey. For procurement directors and regulatory affairs heads, this event necessitates immediate action. The recall impacts multiple lot codes, specifically P061001 through P061023, with expiration dates ranging from July 2025 to January 2027. While a Class III classification indicates that the probability of adverse health consequences is remote, the failure to meet impurity specifications for Pitavastatin Calcium is a critical quality lapse. This directly impacts Teva Pharmaceuticals' ability to supply this product and underscores the imperative for all companies sourcing finished drug products or active pharmaceutical ingredients (APIs) from overseas manufacturers to maintain rigorous oversight of quality control and compliance.
Quality Control Lapses at Orient Pharma's Yunlin Plant Impact Pitavastatin Calcium Supply
The core issue identified in the D-0526-2025 recall is the failure of Pitavastatin Tablets to meet impurity and degradation specifications. This indicates potential deficiencies in the manufacturing processes or quality control systems at Orient Pharma Co., Ltd.'s Yunlin County, Taiwan facility. Impurities and degradation products, even at low levels, can compromise the stability, efficacy, and safety profile of a pharmaceutical product like Pitavastatin Calcium, a statin used to lower cholesterol. Although the FDA has assigned a Class III classification, suggesting a low risk of serious health consequences, such a quality failure is a clear regulatory non-compliance. For supply chain VPs, this incident highlights the inherent risks associated with outsourced manufacturing if not managed with stringent quality assurance protocols. It mandates a critical review of existing supplier qualification programs, particularly for facilities in regions like Taiwan, to ensure that manufacturers adhere to cGMP standards for product stability and purity. Companies must assess whether their current audit processes are sufficient to detect systemic quality control weaknesses before they manifest as product recalls, thereby protecting patient safety and maintaining market supply for essential drugs.
Direct Supply Chain Impact: Teva Pharmaceuticals' Exposure and Broader Sourcing Risks from Taiwan
Teva Pharmaceuticals, Parsippany, NJ, bears the immediate brunt of this recall, as Orient Pharma Co., Ltd. manufactured the affected Pitavastatin Tablets for them. The distribution of 57,504 bottles exclusively to New Jersey means Teva's procurement and logistics teams must manage the retrieval and disposition of these products, incurring significant operational costs and potential revenue losses. This event underscores the critical vulnerability of relying on a single manufacturing site for a finished drug product, even when the primary manufacturer is a contract organization. For business development executives and procurement directors, this situation serves as a stark reminder of the need for supply chain resilience. Companies sourcing from specific geographic regions, such as Taiwan, must conduct thorough risk assessments, considering not only geopolitical factors but also the regulatory compliance history and quality performance of individual manufacturing facilities. Diversifying manufacturing partners and establishing robust contingency plans are essential strategies to mitigate the impact of such recalls on market supply and patient access to critical medications like Pitavastatin Calcium.
Strategic Sourcing and Qualification for Pitavastatin Calcium Alternatives
In light of the ongoing recall of Pitavastatin Tablets, procurement teams must immediately initiate efforts to identify and qualify alternative manufacturers for Pitavastatin Calcium, either as a finished drug product or as an active pharmaceutical ingredient (API). The qualification process for a new pharmaceutical supplier is complex and time-consuming, typically involving comprehensive facility audits, analytical method transfers, stability studies, and the generation of extensive documentation for regulatory submissions. Regulatory affairs heads understand that any change in API or finished product manufacturer for an approved drug like Pitavastatin requires an amendment to the existing Abbreviated New Drug Application (ANDA). This process can take 12 to 24 months, depending on the scope and complexity of the changes and the regulatory agency's review timelines. Therefore, proactive identification and pre-qualification of backup suppliers are not merely best practices but critical components of a resilient supply chain strategy. Companies must invest in a robust supplier management program to ensure continuity of supply and compliance, preventing market shortages and safeguarding patient health.
Regulatory Compliance Outlook and Remediation for Orient Pharma Co., Ltd.
The D-0526-2025 recall of Pitavastatin Tablets by Orient Pharma Co., Ltd. is currently classified as "Ongoing." As a firm-initiated, voluntary action, Orient Pharma is expected to conduct a comprehensive root cause analysis to determine why the product failed impurity and degradation specifications. Following this, the company must implement robust Corrective and Preventive Actions (CAPA) to address the identified deficiencies and prevent recurrence. The FDA will closely monitor these remediation efforts, and the adequacy of the CAPA plan will be critical for Orient Pharma's future regulatory standing. For companies with existing or prospective sourcing relationships with Orient Pharma, this event necessitates heightened due diligence. Regulatory affairs professionals should track the progress of Orient Pharma's remediation and assess its effectiveness. Failure to adequately address the quality issues could lead to further FDA enforcement actions, such as a Warning Letter or an Import Alert, which would severely impact the company's ability to supply the U.S. market. This underscores the need for continuous supplier performance monitoring and a clear understanding of potential regulatory escalation pathways.